Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | EIF4E | P06730 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 4/20 | 0.42 |
| ▸ | ATG7 | O95352 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12150458 | 0.87 | LMNA (0.45) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL9780439 | 0.85 | LMNA (0.59) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL13320587 | 0.85 | LMNA (0.59) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL13352081 | 0.85 | LMNA (0.59) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL6917119 | 0.84 | LMNA (0.42) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL9780402 | 0.83 | ATG7 (0.58) | ATG7 | |
| SCHEMBL12300351 | 0.81 | LMNA (0.44) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL17232105 | 0.79 | PNP (0.57) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL17232112 | 0.79 | LMNA (0.57) | ADORA3LMNAPNPADORA1SMN1; SMN2 | |
| SCHEMBL6914219 | 0.79 | LMNA (0.40) | ADORA3LMNAPNPADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | BOOJAMRA CONSTANTINE G | 2011-03-24 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | ADORA3 936/4885LMNA 2918/4885PNP 3/4885 |
| US-20110071101-A1 | Nucleoside Phosphonate Analogs | TYMP, PNP, NUDT1 | ADORA3 167/4885LMNA 1265/4885PNP 2/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | ADORA3 936/4885LMNA 2918/4885PNP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.